Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Twist Bioscience Corporation (NASDAQ: TWST) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a mid-cap growth and value biotech company focused on synthetic DNA tools and a silicon-based DNA synthesis platform, Twist uses its filings to report financial performance, governance changes and other material events.
Investors can review current and historical 8-K reports, which for Twist have included announcements of quarterly and full-year financial results, as well as board and committee changes. For example, recent 8-K filings describe the release of financial results for specific quarters and fiscal years, and the appointment of a new director to the board and audit committee, along with associated compensation arrangements.
In addition to 8-Ks, users can access Twist’s annual reports on Form 10-K and quarterly reports on Form 10-Q via the SEC feed. These documents typically contain detailed discussions of results of operations, risk factors, and business descriptions related to Twist’s synthetic DNA platform, research tools and geographic operations. Proxy materials and equity compensation plan disclosures can also be reviewed to understand governance practices and incentive structures.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, helping readers quickly interpret complex documents such as lengthy 10-Ks or detailed 10-Qs. Real-time updates from EDGAR ensure that new filings appear promptly, while Form 4 and related insider transaction reports can be monitored to see equity awards and other reportable insider activity. Together, these resources support a deeper understanding of TWST’s regulatory disclosures and corporate developments.
Twist Bioscience Corporation files its annual report describing operations for the year ended September 30, 2025, highlighting growth in synthetic biology, next-generation sequencing tools and biopharma services. The company reported $376.6 million in revenue, including $215.1 million from healthcare, $93.2 million from chemicals/materials, $65.9 million from academic research and $2.4 million from food/agriculture.
Twist continues to scale its silicon-based DNA synthesis platform, expand Express gene and IgG offerings, and deepen its antibody discovery business. Despite revenue growth, it recorded a net loss of $77.7 million and an accumulated deficit of $1,319.6 million, reflecting ongoing investment in manufacturing, R&D and commercialization. As of September 30, 2025, Twist had 442 revenue-generating partnerships and a deal under which XOMA Royalty paid $15 million for 50% of future milestones and royalties from existing collaborations, while Twist retained all upfront and service revenue.
Twist Bioscience Corporation furnished an 8-K to announce financial results for its fiscal fourth quarter and full fiscal year ended September 30, 2025. The company issued a press release on November 14, 2025, and attached it as Exhibit 99.1 titled “Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2025 Financial Results.”
The disclosure was made under Item 2.02 (Results of Operations and Financial Condition) and is being furnished, not filed, meaning it is not subject to Section 18 liability and is not incorporated by reference unless specifically stated. Twist’s common stock trades on the Nasdaq Global Select Market under the symbol TWST.
Twist Bioscience (TWST) insider Dennis Cho reported a sale of 1,019 shares of common stock at $32.0794 on 11/03/2025. According to the filing, this was a mandated “sell to cover” tied to the vesting of Restricted Stock Units to satisfy tax withholding obligations, not a discretionary trade. Following the transaction, Cho beneficially owns 120,694 shares, held directly. His role is listed as Senior Vice President, Chief Legal Officer & Corporate Secretary.
Twist Bioscience Corp (TWST) reported an insider transaction by President and COO Patrick John Finn. On 11/03/2025, he disposed of 2,755 shares of common stock at a price of $32.0794 per share.
The filing states these shares were sold to satisfy tax withholding obligations related to the vesting of Restricted Stock Units under the company’s equity incentive plans, a mandated “sell to cover” and not a discretionary trade by the reporting person. Following the transaction, he directly beneficially owned 265,919 shares.
Twist Bioscience (TWST) insider Paula Green, SVP of Human Resources, reported a transaction on 11/03/2025. She sold 1,084 shares of common stock at $32.0794 per share. According to the footnote, the sale was a mandated “sell to cover” to satisfy tax withholding upon the vesting of Restricted Stock Units and did not represent a discretionary trade. Following the transaction, she beneficially owns 142,187 shares directly.
Twist Bioscience (TWST) CEO and director Emily M. Leproust reported a Form 4 transaction: she sold 4,887 shares of common stock on 11/03/2025 at $32.0794 per share.
According to the footnote, the sale was a mandated “sell to cover” to satisfy tax withholding upon RSU vesting, and not a discretionary trade. Following the transaction, she beneficially owns 733,922 shares directly.
She also holds employee stock options, including 266,539 at $26.66 expiring 11/18/2028 and 150,879 at $8.82 expiring 09/28/2027.
Twist Bioscience (TWST) disclosed an insider transaction by its Chief Accounting Officer, Robert F. Werner. On 11/03/2025, he sold 160 shares of common stock at $32.0794 in a mandated sell-to-cover to satisfy tax withholding arising from the vesting of restricted stock units under the company’s equity plan. Following the transaction, his beneficial ownership stood at 50,870 shares.
Twist Bioscience (TWST) filed a Form 4 reporting an insider tax-related sale. On 10/30/2025, a company officer executed a mandated "sell-to-cover" of 6,515 shares of common stock at $31.4443 per share to satisfy tax withholding tied to the vesting of Performance Stock Units. The filing notes these were not discretionary trades.
Following the transaction, the reporting person directly owned 121,713 shares. The insider is identified as Senior Vice President, Chief Legal Officer & Corporate Secretary.
Twist Bioscience (TWST) reported an insider transaction by President and COO Patrick John Finn. On 10/30/2025, he sold 17,606 shares of common stock at $31.4443 per share, coded “S.” The filing states these shares were sold solely to cover tax withholding triggered by the vesting of Performance Stock Units under a mandated “sell to cover” election in the company’s equity plans, indicating they were not discretionary trades.
Following the transaction, Finn beneficially owns 268,674 shares, held directly.
Twist Bioscience (TWST) reported an insider transaction by its SVP of Human Resources, Paula Green. On 10/30/2025, she sold 6,920 shares of common stock (transaction code S) at $31.4443 per share. The filing states these shares were sold to satisfy tax withholding obligations from vesting Performance Stock Units via a mandated “sell to cover,” indicating they were not discretionary trades. Following the transaction, she beneficially owned 143,271 shares, held directly.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
